The Expedited Access Premarket Approval Application for Unmet Medical Needs for Life Threatening or Irreversibly Debilitating Diseases or Conditions program, would involve more engagement with FDA staff to collaboratively collect appropriate data to support product approval, expediting the timeline for patients to access such devices, according to an FDA news release.
Unlike other EAPs that focus on expediting premarket review of a device, this particular program is aimed toward reducing the time products are spent in development.
“The program allows manufacturers to engage early and often with the agency. We expect most devices that enter this program will be in the pre-clinical trial phase,” said Jeffrey Shuren, MD, director of the FDA’s Center for Devices and Radiological Health, in the news release.
The FDA has issued a draft guidance on this EPA. It is open for comments for the next 90 days.
More Articles on Medical Devices:
Many Approved Pediatric Devices Not Tested on Pediatric Patients
GS1 Healthcare US Releases UDI Implementation Guide
Global Insulin Delivery Devices Market to Reach $14B by 2019
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.